





Hereditary Breast and Ovarian Cancers

Comprehensive BRCA1 & BRCA2 gene testing

(SNVs, InDels and CNVs by Next Generation Sequencing





Indications









NCCN guidelines recommends germline BRCA1 & BRCA2 testing

Personal History

- 1. Breast cancer at ≤50 years
- 2. Ovarian Cancer
- 3. >1 primary breast cancer
- 4. Male breast cancer
- 5. Triple negative breast cancer
- 6. Pancreatic cancer with breast and/or ovarian cancer
- 7. Prostate cancer with breast and/or ovarian cancer
- 8. Ashkenazi Jewish ancestry

Family History:

- 1. >2 relatives with breast cancer at <50 years
- 2. >3 relatives with breast cancer at any age
- 3. BRCA1 and BRCA2 positive family members

Clinical Benefits

Personal & Familial risk assessment

Early detection for better clinical outcome

Risk management & disease prevention through active surveillance and prophylactic surgeries


Risk estimation for secondary cancers and relapse

Determines PARPi eligibility and platinum sensitivity

Germline test details

Test Code	Test Name	Technology	Test Information	TAT
MGM179	BRCA1 and BRCA2 gene analysis	Next Generation Sequencing	Complete coding regions and intron exon boundaries covered	14 working days
MGM178	BRCA1 & BRCA2 deletion/duplication analysis	Digital MLPA	Deletion or duplication analysis	14 working days
MGM194	Hereditary cancer panel (BRCA1 and BRCA2 along with other 143 genes)	Next Generation Sequencing	Complete coding regions and intron exon boundaries of 143 genes including <i>BRCA1</i> and <i>BRCA2</i> genes covered	21 working days
MGM1841	Comprehensive Hereditary Cancer panel	Next Generation Sequencing	Mutation analysis of 143 genes and deletion/duplication analysis of 30 genes including <i>BRCA1</i> and <i>BRCA2</i> genes	21 working days

Tumor BRCA1 & BRCA2 tests



Sample Type: FFPE Tissue Block for tumor tests I Peripheral Blood in Streck Tube (10ml X 2) for liquid biopsy test